-
EP2398901
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP2398901
| EP2398901 - JARID1B FOR TARGET GENE OF CANCER THERAPY AND DIAGNOSIS [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 18.10.2013 Database last updated on 03.09.2024 | Most recent event Tooltip | 18.10.2013 | Application deemed to be withdrawn | published on 20.11.2013 [2013/47] | Applicant(s) | For all designated states Oncotherapy Science, Inc. 2-1, Sakado 3-chome Takatsu-ku Kawasaki-shi Kanagawa 213-0012 / JP | [2011/52] | Inventor(s) | 01 /
NAKAMURA, Yusuke c/o THE UNIVERSITY OF TOKYO 3-1 Hongo 7-chome Bunkyo-ku Tokyo 113-8654 / JP | 02 /
HAMAMOTO, Ryuji c/o THE UNIVERSITY OF TOKYO 3-1 Hongo 7-chome Bunkyo-ku Tokyo 113-8654 / JP | 03 /
TSUNODA, Takuya c/o ONCOTHERAPY SCIENCE INC. 2-1 Sakado 3-chome Takatsu-ku Kawasaki-shi Kanagawa 213-0012 / JP | [2011/52] | Representative(s) | Vossius & Partner Patentanwälte Rechtsanwälte mbB Siebertstrasse 3 81675 München / DE | [N/P] |
| Former [2011/52] | Vossius & Partner Siebertstrasse 4 81675 München / DE | Application number, filing date | 10743496.1 | 27.01.2010 | WO2010JP00441 | Priority number, date | US20090208432P | 23.02.2009 Original published format: US 208432 P | [2011/52] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2010095364 | Date: | 26.08.2010 | Language: | EN | [2010/34] | Type: | A1 Application with search report | No.: | EP2398901 | Date: | 28.12.2011 | Language: | EN | The application published by WIPO in one of the EPO official languages on 26.08.2010 takes the place of the publication of the European patent application. | [2011/52] | Search report(s) | International search report - published on: | JP | 26.08.2010 | (Supplementary) European search report - dispatched on: | EP | 26.10.2012 | Classification | IPC: | G01N33/574, C12N15/09, A61K31/713, A61P35/00, C12N15/113, C12Q1/68, G01N33/15 | [2012/48] | CPC: |
A61K31/713 (EP,US);
A61P35/00 (EP);
A61P35/02 (EP);
C12N15/113 (EP,US);
C12Q1/48 (EP,US);
C12Q1/6886 (EP,US);
G01N33/574 (EP,US);
C12N2310/14 (EP,US);
C12Q2600/136 (EP,US);
|
| Former IPC [2011/52] | C12N15/09, A61K31/713, A61P35/00, C12N15/113, C12Q1/68, G01N33/15 | Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR [2011/52] | Title | German: | JARID1B FÜR EIN ZIELGEN VON KREBSTHERAPIE UND -DIAGNOSE | [2011/52] | English: | JARID1B FOR TARGET GENE OF CANCER THERAPY AND DIAGNOSIS | [2011/52] | French: | JARID1B EN TANT QUE GÈNE CIBLE D'UN TRAITEMENT ANTICANCÉREUX ET D'UN DIAGNOSTIC DE CANCER | [2011/52] | Entry into regional phase | 22.09.2011 | National basic fee paid | 22.09.2011 | Search fee paid | 22.09.2011 | Designation fee(s) paid | 22.09.2011 | Examination fee paid | Examination procedure | 22.09.2011 | Examination requested [2011/52] | 16.04.2012 | Amendment by applicant (claims and/or description) | 24.05.2013 | Application deemed to be withdrawn, date of legal effect [2013/47] | 01.07.2013 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2013/47] | Fees paid | Renewal fee | 25.01.2012 | Renewal fee patent year 03 | 28.01.2013 | Renewal fee patent year 04 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [X]CN101239181 (SHANGHAI INST BIOL SCIENCES [CN]) [X] 1-3,16 * the whole document *; | [X] - A. G. SCIBETTA ET AL, "Functional Analysis of the Transcription Repressor PLU-1/JARID1B", MOLECULAR AND CELLULAR BIOLOGY, (20071015), vol. 27, no. 20, doi:10.1128/MCB.00274-07, ISSN 0270-7306, pages 7220 - 7235, XP055041509 [X] 1-3,16 * the whole document * DOI: http://dx.doi.org/10.1128/MCB.00274-07 | International search | [X] - YAMANE K. ET AL., "PLU-1 is an H3K4 demethylase involved in transcriptional repression and breast cancer cell proliferation.", MOL. CELL, (2007), vol. 25, pages 801 - 812, XP008151026 DOI: http://dx.doi.org/10.1016/j.molcel.2007.03.001 | [X] - BARRETT A. ET AL., "Breast cancer associated transcriptional repressor PLU-1/JARID1B interacts directly with histone deacetylases.", INT. J. CANCER, (2007), vol. 121, pages 265 - 275, XP055041545 DOI: http://dx.doi.org/10.1002/ijc.22673 | [X] - LU P.J. ET AL., "A novel gene (PLU-1) containing highly conserved putative DNA/chromatin binding motifs is specifically up-regulated in breast cancer.", J. BIOL. CHEM., (1999), vol. 274, pages 15633 - 15645, XP055041546 DOI: http://dx.doi.org/10.1074/jbc.274.22.15633 | [X] - BARRETT A. ET AL., "PLU-1 nuclear protein, which is upregulated in breast cancer, shows restricted expression in normal human adult tissues: a new cancer/testis antigen?", INT. J. CANCER, (2002), vol. 101, pages 581 - 588, XP055041548 DOI: http://dx.doi.org/10.1002/ijc.10644 | [X] - TAN K. ET AL., "Human PLU-1 has transcriptional repression properties and interacts with the developmental transcription factors BF-1 and PAX9.", J. BIOL. CHEM., (2003), vol. 278, pages 20507 - 20513, XP055041549 DOI: http://dx.doi.org/10.1074/jbc.M301994200 | [X] - XIANG Y. ET AL., "JARID1B is a histone H3 lysine 4 demethylase up-regulated in prostate cancer.", PROC. NATL. ACAD. SCI. USA, (2007), vol. 104, pages 19226 - 19231, XP055041550 DOI: http://dx.doi.org/10.1073/pnas.0700735104 | [A] - ROESCH A. ET AL., "RBP2-H1/JARID1B is a transcriptional regulator with a tumor suppressive potential in melanoma cells.", INT. J. CANCER, (2008), vol. 122, pages 1047 - 1057, XP008151025 DOI: http://dx.doi.org/10.1002/ijc.23211 |